Structure Therapeutics Inc. (GPCR) Soars 29.36% on Pfizer's Drug Discontinuation

On April 17, 2025, Structure Therapeutics Inc. (GPCR) surged by 29.36% in pre-market trading, marking a significant rise in its stock price.

This surge in Structure Therapeutics' stock price can be attributed to the recent announcement by Pfizer (PFE) that it has discontinued the development of its obesity drug candidate, danuglipron. This decision has led to a rally in the shares of smaller obesity drugmakers, including Structure Therapeutics and Viking Therapeutics (VKTX).

Investors are optimistic about the prospects of Structure Therapeutics, as the discontinuation of Pfizer's obesity drug candidate opens up opportunities for other companies in the same field. The market is anticipating that Structure Therapeutics may benefit from the reduced competition and increased demand for effective obesity treatments.

The positive sentiment surrounding Structure Therapeutics is further bolstered by the company's ongoing research and development efforts in the obesity treatment space. With a strong pipeline of potential therapies, Structure Therapeutics is well-positioned to capitalize on the growing demand for effective weight management solutions.